Efficacy and Safety of Upadacitinib in Moderate|to|Severe Atopic ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

Conclusions and relevance: In this analysis of follow-up data from 2 randomized clinical trials, longer-term treatment of adolescents and adults ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

Meaning This follow-up analysis of 2 randomized clinical trials found that continuous upadacitinib treatment showed a favorable longer-term ...

Efficacy and Safety of Upadacitinib in Moderate-to-Severe Atopic ...

Conclusions. In conclusion, our study has provided preliminary proof that upadacitinib was an effective and safe targeted therapy for moderate ...

Safety of upadacitinib in moderate-to-severe atopic dermatitis

Upadacitinib is a selective reversible Janus kinase (JAK) inhibitor with established efficacy in moderate-to-severe atopic dermatitis (AD).

Safety and efficacy of upadacitinib in combination with topical ...

Systemic therapies are typically combined with topical corticosteroids for the management of moderate-to-severe atopic dermatitis. Upadacitinib is an oral ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With ...

Findings This randomized, blinded, head-to-head comparator clinical trial of 673 patients with moderate-to-severe AD demonstrated clinically ...

734 - Efficacy and safety of upadacitinib vs dupliumab in adults and ...

Treatment of moderate-to-severe AD with upadacitinib demonstrated superiority versus dupilumab for the primary endpoint of simultaneous ...

AbbVie Presents Long-Term Data Further Supporting the Efficacy ...

Upadacitinib (15 mg and 30 mg) was generally well tolerated, and the safety data in the long-term extension of the three studies were consistent ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and ...

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, ...

Efficacy and safety of switching from dupilumab to upadacitinib ...

Upadacitinib was well-tolerated and maintained high levels of skin clearance and itch improvement through 40 weeks in patients with moderate-to- ...

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib ...

The analysis evaluated the efficacy of upadacitinib (15 mg or 30 mg) in patients with moderate-to-severe atopic dermatitis (AD) stratified by ...

Upadacitinib in adults with moderate to severe atopic dermatitis

A dose-response relationship was observed for upadacitinib efficacy; the 30-mg once-daily dose showed the greatest clinical benefit. Dose- ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

trials, longer-term treatment of adolescents and adults with moderate to severe atopic dermatitis with upadacitinib demonstrated a favorable ...

Efficacy and safety of switching from dupilumab to upadacitinib ...

Upadacitinib was well-tolerated and maintained high levels of skin clearance and itch improvement through 40 weeks in patients with moderate-to-severe atopic ...

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and ...

Upadacitinib and dupilumab are two treatment options for atopic dermatitis. Upadacitinib is an oral, small-molecule Janus kinase inhibitor that ...

43049 Efficacy and Safety of Upadacitinib in Adults and Adolescents ...

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by eczematous morphology and intense pruritus. Previous clinical trials ...

Upadacitinib in adults with moderate to severe atopic dermatitis

The mean (SE) primary efficacy end point was 39% (6.2%), 62% (6.1%), and 74% (6.1%) for the upadacitinib 7.5-, 15-, and 30-mg groups, respectively, versus 23% ( ...

Efficacy and Safety of Upadacitinib in Patients With Moderate to ...

Conclusions and Relevance: In this analysis of follow-up data from 2 randomized clinical trials, longer-term treatment of adolescents and adults with moderate ...

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan

Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present ...

Efficacy and safety of upadacitinib for the treatment of moderate-to ...

Across all the included studies, upadacitinib significantly improved local and general physical signs in patients with moderate to severe AD.